Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2009-02-24
2010-12-28
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S399000
Reexamination Certificate
active
07858584
ABSTRACT:
The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 μg/kg to 36 μg/kg of an FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof. In yet another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
REFERENCES:
patent: 4296100 (1981-10-01), Franco
patent: 4378347 (1983-03-01), Franco
patent: 4956455 (1990-09-01), Esch et al.
patent: 5137510 (1992-08-01), VanDeripe
patent: 5137734 (1992-08-01), Spiegelman et al.
patent: 5155214 (1992-10-01), Baird et al.
patent: 5155217 (1992-10-01), Goldfarb et al.
patent: 5213570 (1993-05-01), VanDeripe
patent: 5238916 (1993-08-01), Goldfarb et al.
patent: 5244460 (1993-09-01), Unger et al.
patent: 5269326 (1993-12-01), Verrier
patent: 5302702 (1994-04-01), Seddon et al.
patent: 5310883 (1994-05-01), Seddon et al.
patent: 5314872 (1994-05-01), Kato et al.
patent: 5352589 (1994-10-01), Bergonzoni et al.
patent: 5371206 (1994-12-01), Seddon et al.
patent: 5387673 (1995-02-01), Seddon et al.
patent: 5439818 (1995-08-01), Fiddes et al.
patent: 5464774 (1995-11-01), Baird et al.
patent: 5491220 (1996-02-01), Seddon et al.
patent: 5514566 (1996-05-01), Fiddes et al.
patent: 5604293 (1997-02-01), Fiddes et al.
patent: 5612211 (1997-03-01), Wilson et al.
patent: 5750659 (1998-05-01), Basilico et al.
patent: 5792453 (1998-08-01), Hammond et al.
patent: 5941868 (1999-08-01), Kaplan et al.
patent: 6309370 (2001-10-01), Haim et al.
patent: 6440934 (2002-08-01), Whitehouse
patent: 6451303 (2002-09-01), Whitehouse et al.
patent: 7511019 (2009-03-01), Whitehouse et al.
patent: 2002/0072489 (2002-06-01), Whitehouse
patent: 2003/0148968 (2003-08-01), Hammond et al.
patent: 2003/0166550 (2003-09-01), Whitehouse
patent: 2005/0143298 (2005-06-01), Whitehouse
patent: 0 228 449 (1986-12-01), None
patent: 0 835 932 (1998-04-01), None
patent: WO 86/07595 (1986-12-01), None
patent: WO 89/04832 (1989-06-01), None
patent: WO 97/23256 (1997-07-01), None
patent: WO 00/13701 (2000-03-01), None
Abraham et al., “Human Basic Fibroblast Growth Factor: Nucleotide Sequence and Genomic Organization,”European Molecular Biology Organization Journal, 1986, pp. 2523-2528, vol. 5(10).
Anderson, “Gene Therapy for Genetic Diseases,”Human Gene Therapy, 1994, pp. 281-282, vol. 5.
Banai et al., “Angiogenic-Induced Enhancement of Collateral Blood Flow to Ischemic Myocardium by Vascular Endothelial Growth Factor in Dogs,”Circulation, 1994, pp. 2183-2189, vol. 89(5).
Barinaga, “Step Taken Toward Improved Vectors for Gene Transfer,”Science, 1994, p. 1326, vol. 266.
Barr et al., “Efficient Catheter-Mediated Gene Transfer into the Heart using Replication-Defective Adenovirus,”Gene Therapy, 1994, pp. 51-58, vol. 1.
Battler et al., “Intracoronary Injection of Basic Fibroblast Growth Factor Enhances Angiogenesis in Infarcted Swine Myocardium,”Journal of the American College of Cardiology, 1993, pp. 2001-2006, vol. 22(7).
Bikfalvi et al., “Biological Roles of Fibroblast Growth Factor-2,”Endocrine Reviews, 1997, pp. 26-45, vol. 18.
Bombardini et al., “The Coronary Angiogenetic Effect of Heparin: Experimental Basis and Clinical Evidence,”Angiology, 1997, pp. 969-976, vol. 48, No. 11.
Bork et al., “Go Hunting in Sequence Databases but Watch Out for the Traps,”Trends in Genetics, 1996, pp. 425-427, vol. 12, No. 10.
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,”Genome Research, 2000, pp. 398-400, vol. 10.
Brenner, “Errors in Genome Function,”Trends in Genetics, 1999, pp. 132-133, vol. 15, No. 4.
Brown, “Gene Therapy ‘Oversold’ by Researchers, Journalists,”The Washington Post, 1995, pp. A1 and A22.
Burgess et al., “The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins,”Annual Review of Biochemistry, 1989, pp. 575-606, vol. 58.
Challita et al., “Lack of Expression from a Retroviral Vector after Transduction of Murine Hematopoietic Stem Cells is Associated with Methylation In Vivo,”Proceedings of the National Academy of Science USA, 1994, pp. 2567-2571, vol. 91.
Clements et al., “Activation of Fibroblast Growth Factor (FGF) Receptors by Recombinant Human FGF-5,”Oncogene, 1993, pp. 1311-1316, vol. 8.
Coghlan, “Gene Dream Fades Away,”New Scientist, 1995, pp. 14-15, vol. 148(2005).
Corallini et al., “Promotion of Tumour Metastases and Induction of Angiogenesis by Native HIV-1 Tat Protein from BK Virus//tat Transgenic Mice,”AIDS, 1996, pp. 701-710, vol. 10(7).
Coulier et al., “Putative Structure of the FGF6 Gene Product and Role of the Signal Peptide,”Oncogene, 1991, pp. 1437-1444, vol. 6.
Deroanne et al., Angiogenesis by Fibroblast Growth Factor 4 Is Mediated Through an Autocrine Up-Regulation of Vascular Endothelial Growth Factor Expression,Cancer Research, 1997, pp. 5590-5597, vol. 57, No. 24.
Doerks et al., “Protein Annotation: Detective Work for Function Prediction,”Trends in Genetics, 1998, pp. 248-250, vol. 14, No. 6.
Fisher et al., “Recombinant Adeno-Associatied Virus for Muscle Directed Gene Therapy,”Nature Medicine, 1997, pp. 306-312, vol. 3(3).
Folkman, “Angiogenic Therapy of the Human Heart,”Circulation, 1998, pp. 628-629, vol. 97.
Galzie et al., “Fibroblast Growth Factors and Their Receptors,”Biochem Cell Biol., 1997, pp. 669-685, vol. 75.
Giordano et al., “Intracoronary Gene Transfer of Fibroblast Growth Factor-5 Increases Blood Flow and Contractile Function in an Ischemic Region of the Heart,”Nature Medicine, 1996, pp. 534-539, vol. 2(5).
Giordano et al., “Reduced Myocardial Ischemia After Recombinant Adenovirus Mediated In-Vivo Fibroblast Growth Factor-5 Gene Transfer,”Journal of Investigative Medicine, 1995, p. 278A, vol. 3.
Guzman et al., “Efficient Gene Transfer into Myocardium by Direct Injection of Adenovirus Vectors,”Circulation Research, 1993, pp. 1202-1207, vol. 73(6).
Harada et al., “Basic Fibroblast Growth Factor Improves Myocardial Function in Chronically Ischemic Porcine Hearts,”Journal of Clinical Investigation, 1994, pp. 623-630, vol. 94.
Jaroff, “Keys to the Kingdom,”Time, 1996, pp. 24-29, vol. 148(14).
Kass-Eisler et al., “Quantitative Determination of Adenovirus-Mediated Gene Delivery to Rat Cardiac Myoctyes in vitro and in vivo,”Proceedings of the National Academy of Science USA, 1993, pp. 11498-11502, vol. 90.
Kirschner et al., “Basic Fibroblast Growth Factor Protects Against Ecitotoxicity and Chemical Hypoxia in Both Neonatal and Adult Rats,”Journal of Cerebral Blood Flow and Metabolism, 1995, pp. 619-623, vol. 15(4).
Klagbrun, “Angiogenic Factors, Regulators of Blood Supply-Side Biology,”New Biologist, 1991, pp. 745-749, vol. 3(8).
Laham et al., “Intracoronary Basic Fibroblast Growth Factor (FGF-2) in Patients with Severe Ischemic Heart Disease: Results of a Phase I Open-Label Dose Escalation Study,”J. American College of Cardiology, 2000, pp. 2132-2139, vol. 36(7).
Laham et al., “Intrapericardial Delivery
Kavanaugh W. Michael
Whitehouse Martha J.
Alston & Bird LLP
Novartis Vaccines and Diagnostics Inc.
Saoud Christine J
LandOfFree
Angiogenically effective unit dose of FGF and method of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Angiogenically effective unit dose of FGF and method of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiogenically effective unit dose of FGF and method of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4187547